AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23056633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum cesarean section and operative vaginal delivery
Number of subjects: 78166
Study 21070707 — intervention group
Group type: EXPERIMENTAL
Intervention: Double extraction approach (Group 2)
Number of subjects: 59
Study 17629725 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 52
Study 17629725 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 52
Study 15754200 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional 5‐h course on airway management
Number of subjects: 56
Study 15754200 — intervention group
Group type: COMPARATOR
Intervention: Online course with 36 h access and real-time Q&A sessions
Number of subjects: 56
Study 12046342 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (150 mg daily) for 48 weeks
Number of subjects: 38
Study 9459373 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion consumption (220 g onions/d providing 114 mg quercetin/d)
Number of subjects: 18
Study 9459373 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsley consumption (5 g dried parsley/d providing 84 mg apigenin/d)
Number of subjects: 18
Study 9459373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8590510 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mA
Number of subjects: 90
Study 8590510 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mA
Number of subjects: 90
Study 8590510 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mA
Number of subjects: 90
Study 8590510 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mA
Number of subjects: 90
Study 8590510 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mA
Number of subjects: 90
Study 1977265 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence microscopy of erythrocytes
Number of subjects: 14
Study 1977265 — intervention group
Group type: COMPARATOR
Intervention: Traditional solvent extraction qualitative screening test for blood porphyrins
Number of subjects: 14
Study 192685 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibric acid
Number of subjects: 0
Study 192685 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibric acid
Number of subjects: 0
Study 192685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31746448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release (SR) Nifedipine 20 mg
Number of subjects: 16
Study 31746448 — intervention group
Group type: COMPARATOR
Intervention: Immediate Release (IR) Nifedipine 20 mg
Number of subjects: 16
Study 30870163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal tube
Number of subjects: 46
Study 30870163 — intervention group
Group type: COMPARATOR
Intervention: Control (no nasopharyngeal tube)
Number of subjects: 46
Study 28259723 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 58
Study 28259723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25203421 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (20 g·d(‐1) + placebo)
Number of subjects: 9
Study 25203421 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (0.3 g·kg(‐1) + placebo)
Number of subjects: 9
Study 25203421 — intervention group
Group type: EXPERIMENTAL
Intervention: Coingestion (Creatine + Sodium Bicarbonate + placebo)
Number of subjects: 9
Study 25203421 — intervention group
Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 9
Study 23361456 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus letrozole
Number of subjects: 146
Study 23361456 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ovarian drilling
Number of subjects: 146
Study 23361456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 21276585 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with CAD
Number of subjects: 1775
Study 19447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative disc height < 4mm
Number of subjects: 166
Study 19447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative disc height > 4mm
Number of subjects: 166
Study 19447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative disc height > 5mm
Number of subjects: 166
Study 19447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative disc height > 7mm
Number of subjects: 166
Study 19447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes (NDI)
Number of subjects: 166
Study 19447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes (VAS neck pain score)
Number of subjects: 166
Study 19447077 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes (VAS arm pain score)
Number of subjects: 166
Study 16980156 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% epidural ropivacaine
Number of subjects: 35
Study 16980156 — intervention group
Group type: COMPARATOR
Intervention: 1% epidural ropivacaine
Number of subjects: 35
Study 14651356 — intervention group
Group type: EXPERIMENTAL
Intervention: [11C]raclopride (D2 antagonist)
Number of subjects: 10
Study 14651356 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 10
Study 10588490 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment (20 pps, 150 mJ) only
Number of subjects: 8
Study 10588490 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 8
Study 10588490 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment first, followed by SRP 6 weeks later
Number of subjects: 8
Study 10588490 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP first, followed by laser therapy 6 weeks later
Number of subjects: 8
Study 8934459 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent articulatory suppression
Number of subjects: 0
Study 8934459 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased delay between stimulation and recall
Number of subjects: 0
Study 8934459 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeating 'the' continuously
Number of subjects: 0
Study 8934459 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting backwards in threes
Number of subjects: 0
Study 8934459 — intervention group
Group type: COMPARATOR
Intervention: Quiet condition
Number of subjects: 0
Study 8934459 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional tactile interference
Number of subjects: 0
Study 8934459 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent articulatory suppression and additional tactile interference combined
Number of subjects: 0
Study 1679390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (10 mg once daily)
Number of subjects: 108
Study 1679390 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (titrated from 0.5 mg to a maximum of 2 mg tds)
Number of subjects: 108
Study 6340976 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac sodium
Number of subjects: 40
Study 6340976 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen
Number of subjects: 40
Study 30969220 — intervention group
Group type: EXPERIMENTAL
Intervention: Second uterine curettage
Number of subjects: 89
Study 30969220 — intervention group
Group type: COMPARATOR
Intervention: No curettage (control)
Number of subjects: 89
Study 28324753 — intervention group
Group type: EXPERIMENTAL
Intervention: Error augmentation feedback during training sessions
Number of subjects: 36
Study 28324753 — intervention group
Group type: COMPARATOR
Intervention: Unaltered, control feedback during training sessions
Number of subjects: 36
Study 25904425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 33
Study 25904425 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 33
Study 25090255 — intervention group
Group type: EXPERIMENTAL
Intervention: Coparenting intervention
Number of subjects: 90
Study 25090255 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple intervention
Number of subjects: 90
Study 25090255 — intervention group
Group type: COMPARATOR
Intervention: Information control group
Number of subjects: 90
Study 22743239 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP3 gene polymorphisms (rs1685354 and rs11235972)
Number of subjects: 1616
Study 22743239 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP3 gene polymorphisms (rs11235972)
Number of subjects: 1616
Study 18670875 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 60
Study 18670875 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 60
Study 17899346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0
Study 17899346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov technique in combination with minimally invasive internal fixation (group I)
Number of subjects: 59
Study 15048331 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical procedure (group II)
Number of subjects: 59
Study 15048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov technique (group I)
Number of subjects: 59
Study 12566647 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous balloon valvuloplasty
Number of subjects: 80
Study 12566647 — intervention group
Group type: COMPARATOR
Intervention: Open commissurotomy
Number of subjects: 80
Study 15512286 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 39
Study 15512286 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 39
Study 15512286 — intervention group
Group type: COMPARATOR
Intervention: Methyl dopa
Number of subjects: 39
Study 7604081 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Hz TENS
Number of subjects: 24
Study 7604081 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-Hz TENS
Number of subjects: 24
Study 7604081 — intervention group
Group type: COMPARATOR
Intervention: Control (no TENS)
Number of subjects: 24
Study 7604081 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger temperature
Number of subjects: 24
Study 2666737 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 34
Study 2666737 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor leukocytic mass
Number of subjects: 34
Study 2666737 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 34
Study 187312 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 (2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU), cyclophosphamide, and methotrexate
Number of subjects: 206
Study 187312 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and methotrexate
Number of subjects: 206
Study 187312 — intervention group
Group type: EXPERIMENTAL
Intervention: Small cell anaplastic carcinoma
Number of subjects: 206
Study 187312 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 206
Study 187312 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermoid carcinoma
Number of subjects: 206
Study 187312 — intervention group
Group type: EXPERIMENTAL
Intervention: Large cell carcinoma
Number of subjects: 206
Study 187312 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (small cell anaplastic carcinoma)
Number of subjects: 206
Study 187312 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders (adenocarcinoma)
Number of subjects: 206
Study 30122637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Group Mapping
Number of subjects: 151
Study 30122637 — intervention group
Group type: EXPERIMENTAL
Intervention: Video 4‐Step Approach
Number of subjects: 151
Study 30122637 — intervention group
Group type: COMPARATOR
Intervention: See one ‐ Do one
Number of subjects: 151
Study 30122637 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 151
Study 25998624 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 665
Study 25998624 — intervention group
Group type: COMPARATOR
Intervention: Parnaparin
Number of subjects: 665
Study 22949107 — intervention group
Group type: EXPERIMENTAL
Intervention: Photohardening therapy (311 nm UVB) for 4-9 weeks
Number of subjects: 16
Study 21866654 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblocking the interior and purgation method (Chinese drugs infused by enteral nutrition tube)
Number of subjects: 60
Study 21866654 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 19732245 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preventive care
Number of subjects: 235
Study 16753439 — intervention group
Group type: EXPERIMENTAL
Intervention: Conveen anal plug
Number of subjects: 16
Study 15273834 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment for ADHD
Number of subjects: 10
Study 11158461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg) administered intravenously or by feeding tube every 72 hours until day of life (DOL) 7, then every 24 hours until DOL 28.
Number of subjects: 103
Study 11158461 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for the same duration as fluconazole.
Number of subjects: 103
Study 11158461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg)
Number of subjects: 103
Study 11158461 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 103
Study 9234567 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/24 hour transdermal nitroglycerin
Number of subjects: 98
Study 9234567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration of mephenytoin
Number of subjects: 0
Study 7952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration of dextromethorphan
Number of subjects: 0
Study 7952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration of caffeine
Number of subjects: 0
Study 7952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of mephenytoin and dextromethorphan
Number of subjects: 0
Study 7952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of mephenytoin and caffeine
Number of subjects: 0
Study 7952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of mephenytoin, dextromethorphan, and caffeine
Number of subjects: 0
Study 7952033 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrokinetic capillary techniques
Number of subjects: 0
Study 3281401 — intervention group
Group type: EXPERIMENTAL
Intervention: Early T-tube removal (postoperative day 4)
Number of subjects: 62
Study 3281401 — intervention group
Group type: COMPARATOR
Intervention: Late T-tube removal (postoperative day 7)
Number of subjects: 62
Study 31978214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction chemotherapy
Number of subjects: 178
Study 31978214 — intervention group
Group type: COMPARATOR
Intervention: Standard induction chemotherapy
Number of subjects: 178
Study 31978214 — intervention group
Group type: EXPERIMENTAL
Intervention: PBC < 1.0
Number of subjects: 178
Study 31978214 — intervention group
Group type: EXPERIMENTAL
Intervention: PBC analysis
Number of subjects: 178
Study 31170797 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved clinical supervision and support
Number of subjects: 125
Study 31170797 — intervention group
Group type: COMPARATOR
Intervention: Actual clinical supervision and support
Number of subjects: 125
Study 28209275 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured Resection (MR)
Number of subjects: 24
Study 28209275 — intervention group
Group type: COMPARATOR
Intervention: Gap Balancing (GB)
Number of subjects: 24
Study 26201426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention
Number of subjects: 87
Study 24231592 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin submicron particle capsules 40 mg 3 times daily
Number of subjects: 0
Study 24231592 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin submicron particle capsules 40 mg twice daily
Number of subjects: 0
Study 24231592 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin submicron particle capsules 20 mg 3 times daily
Number of subjects: 0
Study 24231592 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg loading dose, then 200 mg BID)
Number of subjects: 0
Study 24231592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20598332 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg/kg per day initially, increased to 4 mg/kg per day within 10 days)
Number of subjects: 406
Study 20598332 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (4 mg/kg per day)
Number of subjects: 406
Study 19927544 — intervention group
Group type: EXPERIMENTAL
Intervention: Captisol-enabled budesonide solution (CBIS), 60 microg twice daily
Number of subjects: 12
Study 19927544 — intervention group
Group type: COMPARATOR
Intervention: Conventional budesonide suspension (Pulmicort Respules), 250 microg twice daily
Number of subjects: 12
Study 21255215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg/day)
Number of subjects: 110
Study 21255215 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000-2000 mg/day)
Number of subjects: 110
Study 21255215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 110
Study 16277094 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and oxaliplatin combination treatment (6 cycles of oxaliplatin 85 mg/m2 on days 1 and 15, irinotecan 80 mg/m2 on days 1, 8, and 15)
Number of subjects: 34
Study 12243600 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 400 mg orally 3 times daily
Number of subjects: 151
Study 12243600 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg orally twice daily
Number of subjects: 151
Study 12243600 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 250 mg orally twice daily
Number of subjects: 151
Study 9771641 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelinguistic Milieu Teaching (PMT)
Number of subjects: 58
Study 9771641 — intervention group
Group type: COMPARATOR
Intervention: Responsive Small Group (RSG)
Number of subjects: 58
Study 7669537 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational case intervention (emphasizing progressive disclosure of cases, active leadership style, and educational principles)
Number of subjects: 18
Study 7669537 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 18
Study 2696232 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine therapy
Number of subjects: 74
Study 2696232 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 74
Study 105097 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 20
Study 105097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11963821 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 105
Study 11963821 — intervention group
Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 105
Study 29960741 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy in addition to IF electrical stimulation (group A)
Number of subjects: 46
Study 29960741 — intervention group
Group type: COMPARATOR
Intervention: Only biofeedback therapy (group B)
Number of subjects: 46
Study 29960741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 46
Study 28985325 — intervention group
Group type: EXPERIMENTAL
Intervention: Telereab-HBP (integrated telerehabilitation home-based programme)
Number of subjects: 112
Study 28985325 — intervention group
Group type: EXPERIMENTAL
Intervention: Telereab-HBP
Number of subjects: 112
Study 27810602 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional meal plan diet delivered remotely using FaceTime™ on an iPad (RD/CD)
Number of subjects: 123
Study 27810602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop Light diet enhanced with portion-controlled meals (PCMs) delivered remotely using FaceTime™ on an iPad (RD/eSLD)
Number of subjects: 123
Study 27810602 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet delivered during face-to-face home visits (FTF/CD)
Number of subjects: 123
Study 24461582 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg once daily)
Number of subjects: 16
Study 22507362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand exercise intervention (5 exercise sessions and a home exercise component over a 12 week period) with usual care
Number of subjects: 480
Study 22507362 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 480
Study 20185615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 36
Study 20185615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack
Number of subjects: 36
Study 20185615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 36
Study 17428696 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid internal fixation
Number of subjects: 127
Study 17428696 — intervention group
Group type: COMPARATOR
Intervention: Wire osteosynthesis
Number of subjects: 127
Study 17428696 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger advancements
Number of subjects: 127
Study 17428696 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 127
Study 17428696 — intervention group
Group type: EXPERIMENTAL
Intervention: Genioplasty
Number of subjects: 127
Study 15067624 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride 25 mg, 3 times daily
Number of subjects: 140
Study 15067624 — intervention group
Group type: COMPARATOR
Intervention: Cisapride 10 mg, 3 times daily
Number of subjects: 140
Study 15067624 — intervention group
Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 140
Study 15067624 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride
Number of subjects: 140
Study 12542131 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-task participants (stamped the target with a handheld block)
Number of subjects: 0
Study 12542131 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition-task participants (lifted the block through a target-compatible gap)
Number of subjects: 0